Pharmaceuticals · USA
Track Eli Lilly and Co
Add to watchlistEli Lilly and Company is one of the world’s largest pharmaceutical companies, focused on discovering, developing, manufacturing, and commercialising medicines for major areas of medical need. The company has a strong presence across diabetes, obesity, oncology, immunology, neuroscience, cardiovascular disease, and pain, with products used by patients and healthcare systems around the world.
Eli Lilly’s strength comes from its research base, global pharmaceutical scale, and leadership in high-growth treatment areas such as diabetes and obesity. Medicines such as Mounjaro and Zepbound have made the company one of the most important players in metabolic health, while its wider pipeline gives it exposure to cancer treatment, Alzheimer’s disease, immunology, and other complex conditions. This makes Eli Lilly a major healthcare innovation platform with both defensive pharmaceutical qualities and long-term growth potential from new therapies.
Need deeper analysis on Eli Lilly and Co? ET&A Professional includes full company notes, valuations and models — or commission bespoke research.
Mobile money began as a convenient way to send and receive cash. Today, Africa’s largest telecom operators are moving into lending, savings, insurance and investment products. MTN’s interest in acquiring banking licences raises a bigger question: could the mobile network eventually become more important to African consumer finance than the traditional bank branch?
ET&A Research · 27 August 2026
Nvidia delivered another substantial earnings beat in its fiscal second quarter, with revenue more than doubling year-on-year as demand for AI infrastructure continued to accelerate. Strong Data Center growth, the ramp-up of Vera Rubin and an unusually bullish outlook suggest the AI investment cycle still has considerable room to run, although supply constraints, rising memory costs and China remain important risks.
ET&A Research · 27 August 2026
As AI chips become larger, faster and more memory-intensive, advanced packaging is emerging as a critical performance bottleneck, reshaping semiconductor design, supply chains and the investment opportunity across the industry.
ET&A Research · 25 August 2026
